期刊文献+

退行性心脏瓣膜病患者血清LP(a)、OPN、IRF-4表达及其临床意义 被引量:2

Expressions and clinical significance of serum LP(a),OPN,IRF⁃4 in patients with degenerative heart valve disease
下载PDF
导出
摘要 目的探讨退行性心脏瓣膜病(DHVD)患者血清脂蛋白(a)[LP(a)]、骨桥蛋白(OPN)、干扰素调节因子⁃4(IRF⁃4)表达及其临床意义。方法选取本院120例DHVD患者作为研究组,同期健康体检者115例作为对照组。比较两组血清LP(a)、OPN、IRF⁃4 mRNA水平,分析DHVD发病的影响因素及血清各指标诊断DHVD的价值,并比较治疗3个月后不同疗效患者血清LP(a)、OPN、IRF⁃4 mRNA水平及心功能指标[左心室射血分数(LVEF)、心脏指数(CI)]水平,分析各血清各指标与心功能指标相关性。结果多瓣膜病变患者组、单瓣膜病变患者组及健康体检者血清LP(a)、OPN、IRF⁃4 mRNA水平比较(F=47.427,66.514,36.432),差异有统计学意义(P<0.05);冠心病、吸烟史、高血压、血清LP(a)、OPN、IRF⁃4 mRNA是DHVD发病的重要影响因素(P<0.05);血清各指标中,LP(a)诊断DHVD的曲线下面积(AUC)最大,为0.802,截断值敏感度为70.00%,特异度为86.09%;治疗3个月后,显效者血清LP(a)、OPN水平低于有效者、无效者,IRF⁃4 mRNA水平及LVEF、CI高于有效者、无效者(P<0.05);血清LP(a)、OPN与LVEF、CI存在显著负相关关系,IRF⁃4 mRNA与LVEF、CI存在显著正相关关系,差异有统计学意义(P<0.05)。结论DHVD患者血清LP(a)、OPN、IRF⁃4 mRNA表达异常,是DHVD发生的重要影响因素,在DHVD诊断及评估疗效方面具有较高应用价值。 Objective To investigate the expression of serum lipoprotein(a)[LP(a)],osteopontin(OPN),interferon regulatory factor⁃4(IRF⁃4)in patients with degenerative heart valve disease(DHVD)and its clinical significance.Methods 120 patients with DHVD in our hospital were selected as the study group,and 115 healthy people who were examined during the same period were used as the control group.The serum LP(a),OPN,IRF⁃4 mRNA levels were compared between the two groups.The influencing factors of the incidence of DHVD and the diagnostic value of serum indicators for DHVD were analyzed.The levels of serum LP(a),OPN,IRF⁃4 mRNA and cardiac function indexes[left ventricular ejection fraction(LVEF),cardiac index(CI)]of patients with different therapeutic effects after 3 months of treatment were compared.The correlation between serum indexes and cardiac function indexes was evaluated.Results The serum LP(a),OPN,IRF⁃4 mRNA levels have significant difference in the patients with multi⁃valvular disease and with single⁃valvular disease,and healthy people(F=47.427,66.514,36.432),(P<0.05).Coronary heart disease,smoking history,high blood pressure,serum LP(a),OPN,and IRF⁃4 mRNA are important influencing factors for the onset of DHVD(P<0.05).Coronary heart disease,smoking history,hypertension,serum LP(a),OPN,IRF⁃4 mRNA are important influencing factors of DHVD(P<0.05).Among the various serum indexes,the area under the curve(AUC)for diagnosis of DHVD by LP(a)is the largest,0.802,the sensitivity of the cutoff value is 70.00%,and the specificity is 86.09%.After the treatment for 3 months,the serum LP(a)and OPN levels of the effective patients were lower than those of the effective and ineffective patients,and the IRF⁃4 mRNA levels and LVEF,CI were higher than those of the effective and ineffective(P<0.05).The serum LP(a)and OPN had negative correlation with LVEF and CI.Intersetingly,theIRF⁃4 mRNA had positive correlation with LVEF and CI(P<0.05).Conclusion The abnormal expression of serum LP(a),OPN and IRF⁃4 mRNA in DHVD patients is an important influencing factor of DHVD,and has high application value in the diagnosis and evaluation of DHVD.
作者 王俊华 崔勤涛 韩培立 刘晓晨 WANG Junhua;CUI Qintao;HAN Peili;LIU Xiaochen(Department of cardiovascular surgery,The First affiliated hospital of xinxiang medical college,Weihui Henan,China,453100)
出处 《分子诊断与治疗杂志》 2020年第4期483-486,506,共5页 Journal of Molecular Diagnostics and Therapy
基金 河南省高等学校重点科研项目(17A320017)。
关键词 退行性心脏瓣膜病 脂蛋白(a) 骨桥蛋白 干扰素调节因子⁃4 心功能 诊断 Degenerative heart valve disease Lipoprotein(a) Osteopontin Interferon regulatory factor⁃4 Cardiac function Diagnosis
  • 相关文献

参考文献10

二级参考文献71

  • 1Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the management of patients with valvular heart dig-" ease:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coil Cardiol,2014,63 : e57-185.
  • 2Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused up- date incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coil Cardiol,2008,52 :el-el42.
  • 3Rosenhek R, Zilberszac R, Schemper M, et al. Natural history of very severe aortic stenosis. Circulation ,2010,121 : 151-156.
  • 4Bhattacharyya S, Hayward C, Pepper J, et al. Risk stratification in asymptomatic severe aortic stenosis:a critical appraisal. Eur Heart J,2012,33:2377-2387.
  • 5Alborino D, Hoffmann JL, Foumet PC, et al. Value of exercise tes- ting to evaluate the indication for surgery in asymptomatic patients with valvular aortic stenosis. J Heart Valve Dis, 2002, 11: 204 -209.
  • 6Dujardin KS, Enriquez-Sarano M, Sehaff HV, et al. Mortality andmorbidity of aortic regurgitation in clinical practice. A long-term follow-up study. Circulation, 1999,99 : 1851-1857.
  • 7Ishii K, Hirota Y, Suwa M, et al. Natural history and left ventricu- lar response in chronic aortic regurgitation. Am J Cardiol, 1996, 78:357-361.
  • 8Ben FM, Ayari M, Maatouk F, et al. Percutaneous balloon versus surgical closed and open mitral commissurotomy : seven-year fol- low-up results of a randomized trial. Circulation, 1998, 97: 245 -250.
  • 9Nishimura RA, Otto CM. 2014 ACC/AHA valve guidelines :earli- er intervention for chronic mitral regurgitation. Heart,2014,100: 905 -907.
  • 10Vassileva CM, Mishkel G, McNeely C, et al. Long-term survival of patients undergoing mitral valve repair and replacement : a longitu- dinal analysis of medicare fee-for-service beneficiaries. Circula- tion,2013,127:1870-1876.

共引文献73

同被引文献20

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部